Selecting elderly colorectal cancer patients for adjuvant therapy remains a challenge. Comprehensive geriatric assessment is useful for defining multiple frailty levels and guiding decision-making. The supposed benefit of adjuvant chemotherapy is related to the rate of treatment adherence. To identify factors associated with elderly patient's refusal, toxicity, and treatment completion can improve adherence to adjuvant chemotherapy. Background: Selecting elderly people with colorectal cancer (CRC) for adjuvant chemotherapy is challenging. Comprehensive geriatric assessment (CGA) can help by classifying them according to their frailty profile. The supposed benefit of chemotherapy is on the basis of the rate of treatment adherence. In this study we evaluated tolerance and adherence to tailored-dose adjuvant therapy on the basis of CGA in a cohort of older patients with high-risk stage II and stage III CRC. Patients and Methods: This was a prospective study in 193 consecutive patients aged 75 years or older. On the basis of CGA results, we classified patients as fit, medium fit, or unfit, administering standard therapy, adjusted treatment, and best supportive care, respectively. We recorded planned chemotherapy, toxicity, and completion of the treatment. A logistic multivariate analysis was carried out. Results: Seventeen (15%) of the 141 candidates for chemotherapy (n ¼ 86 fit and n ¼ 55 medium fit) refused treatment; associated factors included polypharmacy (odds ratio [OR], 5.34; 95% confidence interval [CI], 1.55-18.40) and rectal location (OR, 5.61; 94% CI, 1.45-21.49). Of the 105 (74%) patients receiving chemotherapy, 20 (27%) fit and 4 (13%) medium fit patients experienced Grade 3 to 4 toxicity (P ¼ .11) without association to explanatory variables. Approximately 55% of patients treated with chemotherapy received at least 80% of the planned dose (55% fit and 58% medium fit patients; P ¼ .7). Factors associated with completion of chemotherapy were the absence of toxicity (OR, 7.67; 95% CI, 2.41-24.43) and social support (OR, 2.29; 95% CI, 0.08-1.04). Conclusion: CGA is useful for selecting elderly patients for adjuvant chemotherapy, adapting the dose to their frailty profile, and identifying adherence-related factors amenable to modification through CGA-based interventions.
Introduction
Population aging in high-income countries is an indicator of quality health care systems, but the corresponding increase in age-associated diseases also poses particular challenges. A key risk factor for cancer is age, which serves as the nexus for a complex interplay of biological and social risk factors. 1 This epidemiological trend is particularly relevant in the case of colorectal cancer (CRC), the second most common type of tumor in men as well as women. 2 The advent of population-based screening for CRC will probably increase the rate of patients diagnosed at an early stage, who will be candidates for adjuvant treatment. 3 Standard treatment in high-risk stage II and stage III resected CRC patients includes adjuvant chemotherapy with 5-fluorouracil (5-FU) or the oral 5-FU prodrug capecitabine, with or without oxaliplatin. 4, 5 Several studies have shown that the magnitude of the benefit of 5-FU might be similar in elderly and younger patients, but there is disagreement regarding the additional use of oxaliplatin. Most data come from subgroup analyses in clinical trials that include a small number of participants older than the age of 65 years with inconsistent results. [6] [7] [8] [9] [10] Likewise, population-based studies have also provided inconsistent results regarding the benefit of use of oxaliplatin in addition to chemotherapy. [11] [12] [13] In consequence, fluoropyrimidine monotherapy (5-FU or capecitabine) is considered an appropriate option for most elderly patients, instead of combination chemotherapy, which could be limited to selected candidates.
14 Capecitabine is commonly preferred over 5-FU because it is an oral treatment that does not require long-term central venous access, implying reduced cost, hospital stays, and toxicity. 15 However, the potential benefit of chemotherapy is conditioned to the assumption that patients will complete the planned schedule without serious adverse events. 16, 17 Previous studies have consistently reported that oral administration and advanced age are uniformly associated with lower adherence rates. 18, 19 In an attempt to address these challenges, the International Society of Geriatric Oncology 14 and National Comprehensive Cancer
Network guidelines 20 recommend a comprehensive geriatric assessment (CGA) in patients aged 70 years or older before making a decision on cancer treatment. Briefly, CGA is a multidimensional tool that is used to comprehensively evaluate all of the functional, mental, and social aspects of the patient's life that could have a potential effect on the development of the illness and the response to its treatment, guiding clinical interventions to improve them when necessary. Classifying patients according to their frailty profile, CGA can be used to distinguish between those with robust health who could benefit from the same active oncological treatment as younger adults, vulnerable patients eligible for adapted treatment, and disabled (unfit) patients for whom best supportive care is most appropriate. 21 It has been shown that CGA can predict poor treatment outcomes. 22 The aim of this prospective study was to assess tolerance and adherence to tailored-dose adjuvant therapy on the basis of CGA in a cohort of older patients (aged 75 years or older) with high-risk stage II and stage III CRC. We also evaluated predictive factors associated with treatment refusal, toxicity, and treatment completion to explain adherence.
Patients and Methods

Study Group
This was a prospective study conducted at the Institut Català d'Oncologia, a comprehensive cancer center serving a population of approximately 800,000 inhabitants and a reference center for 6 hospitals in a cancer care network, operating within the health region in Barcelona. From May 2008 to September 2016, people with CRC who underwent surgical resection in other general hospitals were referred to our cancer center to determine the need for complementary adjuvant therapy. In keeping with this responsibility, since 2008 the hospital has had an oncogeriatrics unit that incorporates, among other tasks, CGA into the routine clinical assessment of incident CRC in patients aged 75 years and older. Our study population was comprised of all patients with high-risk stage II disease and stage III disease referred to our center after curative resection (R0 surgery with lymph node dissection) for whom there was a consensus on the indication of adjuvant chemotherapy (with or without radiotherapy). 20, 23 According to criteria commonly accepted in clinical practice guidelines, high-risk stage II disease was defined as the presence of at least 1 of the following: pT4 stage, fewer than 12 resected lymph nodes, poorly differentiated histology (Grade 3), evidence of lymphovascular invasion, clinical bowel obstruction, or tumor perforation. 24 We excluded patients who did not undergo radical resection (R1-2 surgery), those with cancer metastases at diagnosis, and those lost to follow-up within 6 months. The ethics committee of the Bellvitge University Hospital approved the study.
The principal investigators at the oncogeriatrics unit recorded, anonymized, and analyzed all data.
Comprehensive Geriatric Assessment and Treatment
A team including a geriatrician and geriatric oncologist assessed all patients within 8 weeks of surgery, and treated them as appropriate. All patients underwent CGA to evaluate functional, nutritional, cognitive, and psychological status as well as comorbidities, concurrent medication, social support, and geriatric syndromes.
We measured functional status using the Barthel Activities of Daily Living scale 25 and the Lawton Index of Instrumental Activities of Daily Living. 26 To assess nutritional status, we asked patients to describe weight loss over the previous 6 months; loss of more than 10% of body weight indicated possible malnutrition. Cognitive status was determined using the Short Portable Mental Status Questionnaire (Pfeiffer test), 27 and mood was assessed using the 4-item Mini-Geriatric Depression Scale. 28 To assess comorbidity, we recorded the number of relevant conditions scoring !3 on the Cumulative Illness Rating Scale for Geriatrics index. Polypharmacy was evaluated according to self-report and review of the patient's medical records. The social environment was considered good if the patient had a primary caregiver, support at home, or a strong circle of friends and family capable of meeting the patient's needs at the time of the evaluation. A geriatric syndrome was determined according to self-reported number of falls in the past 6 months, cognitive impairment, delirium, and urinary and/or fecal incontinence. If the Pfeiffer test indicated cognitive impairment, assessment was completed with a neurocognitive consultation; in case of confirmed cognitive impairment, we considered this to be a geriatric syndrome rather than a comorbid condition to avoid overlap between these 2 domains. We considered incontinence to be a geriatric syndrome if it was not stress incontinence or related to tumor location or surgery. We also used the Vulnerable Elders Survey (VES-13) as a vulnerability screening tool; this consists of 4 groups of questions in relation to age, self-perceived health, difficulties in performing 6 specific activities, and difficulties in performing activities of daily living. 29 Table 1 shows the scores and the cutoff values for all CGA variables.
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Adherence to Adjuvant Treatment in Elderly Patients With CRC According to the modified CGA classification proposed by Balducci and Beghe, 30 we classified patients as "fit" (eligible for full treatment), "medium fit" (eligible for modified treatment), or "unfit" patients (not eligible for curative therapy). Table 2 shows the criteria for classification as well as the therapeutic strategies applied to each. We followed up all patients, including fit and medium fit patients not undergoing any postoperative chemotherapy and unfit patients assigned to best supportive care. A pharmacist visited all patients receiving adjuvant treatment, validating each chemotherapy drug given during each cycle and evaluating adherence, polypharmacy, and potential pharmacological interactions. In Figure 1 we show an algorithm that summarizes how the integration of all this multidimensional information was carried out in the decisionmaking process on CRC adjuvant treatment. In addition to CGA, decision-making on specific therapeutic aspects, such as the choice between oxaliplatin and fluoropyrimidine doublets versus capecitabine monotherapy, was performed according to a shared decision model, taking into account the possible functional sequelae of the treatments and the incremental benefit of combinations. Adverse events were qualified according to National Cancer Institute Common Toxicity Criteria. 31 
Outcome Variables
The follow-up period was defined from the date of CGA assessment to the date of the last visit, which occurred at least 3 months after finishing chemotherapy. We recorded planned chemotherapy (specified at the time of CGA) and completion (defined as completing initially planned chemotherapy course without later modifications or early discontinuation). We recorded adherence according to patients' return of oral chemotherapy. We also noted treatment modifications (delays or dose reductions) and early drug discontinuation for any cause. We defined relative dose intensity (RDI) of chemotherapy use as dose delivered relative to the planned dose, considering rates of 80% or more to be acceptable adherence.
Toxicity was evaluated and graded prospectively before each cycle according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (NCI-CTC) version 3.0/NCI-CTC 4.0 scoring system. Each participant could have more than 1 adverse drug event.
Statistical Analyses
We conducted univariate and multivariate analyses to identify factors associated with treatment refusal, completion, and toxicity. For the univariate screening comparisons, we used Fisher exact test, ManneWhitney U test, or Student t test, as appropriate; variables univariately predictive with P < .1 were entered into the multivariate logistic regression model. We expressed outcomes as adjusted odds ratios (ORs) with 95% confidence intervals (CIs) and considered a significance level of P < .05 in all statistical tests. The probabilities for overall survival (OS) and disease-free survival (DFS) were estimated using the KaplaneMeier method; survival functions were compared using the log rank test. All P values are 2-tailed. All statistical analyses were performed using SPSS version 17 software (SPSS Inc, Chicago, IL).
Results
Patient Characteristics
Of the 198 patients in the initial sample, there were data available on chemotherapy adherence and toxicity in 193. Table 3 shows the baseline patient and tumor characteristics. Patients were predominantly men (63%) and had an overall mean age of 79.6 years (range, 75-89); 36% were aged older than 80, and 9% were older than 85. Most (78%) had a relatively good performance status (Eastern Cooperative Oncology Group performance status <2) at study entry. With regard to tumor characteristics, 142 (74%) patients had a primary tumor located in the colon and 51 (26%) in the rectum. The median follow-up for the entire cohort was 39.13 (range, 0.39-83. 15 
Geriatric Assessment for Tailoring Decisions on Adjuvant Therapy
On the basis of the CGA, we deemed 86 (45%) patients to be fit, 55 (29%) to be medium fit, and 52 (26%) to be unfit. Table 3 shows detailed results from the geriatric assessment. This stratification was used to guide decision-making relating to the best adjuvant treatment for each individual.
Of the 141 patients who were potentially considered candidates for adjuvant therapy according to the CGA criteria, only 105 (74%) patients finally received treatment: 73 (85%) fit participants received standard doses of chemotherapy, and 32 (58%) medium fit participants were treated with reduced dosage. Reasons for not receiving treatment among eligible patients were: surgical complications that delayed the assessment >8 weeks (n ¼ 11), specific contraindication for chemotherapy, such as cardiological comorbidity or renal failure (n ¼ 7), intercurrent process (ischemic cerebrovascular accident; n ¼ 1), or treatment refusal (n ¼ 17). All but 3 fit patients (97%) received capecitabine monotherapy; 2 received capecitabine with oxaliplatin, and 1 was treated with 5-FU with oxaliplatin. To assess adherence, the analysis was restricted to the subgroup of patients considered candidates to receive adjuvant treatment on the basis of the CGA. We then performed univariate and multivariate analyses on different variables to test their association with treatment refusal (Table 4) . In univariate analysis, factors associated with patient refusal were tumor location (25% in rectum vs. 10% in colon; P ¼ .04), polypharmacy (28.1% vs. 8.9%; P ¼ .01), VES-13 score of more than 3 (36.4% vs. 9%; P < .001), and oncogeriatric classification (24.4% medium fit patients vs. 8.6% fit patients; P ¼ .02). In the multivariate model, the only factors that contributed to treatment refusal were polypharmacy (OR, 5.34; 95% CI, 1.55-18.40) and tumor location in rectum (OR, 5.61; 95% CI, 1.45-21.49).
Toxicity
Of the 105 patients who received chemotherapy, 80 (76%) reported 195 adverse events. Twenty (27%) fit and 4 (13%) medium fit patients experienced some kind of Grade 3 to 4 toxicity (P ¼ .11); this included hematologic toxicity in 4 (3.8%) fit patients (P ¼ .31) and nonhematologic toxicity in 18 (24%) fit and 3 (10%) medium fit patients (P ¼ .09). There were no toxicity-related deaths. As expected, the most frequently observed toxicities were fatigue/weakness (44%), hand-foot syndrome (41%), and diarrhea (25%). Table 5 shows a summary of toxicity according to geriatric group. None of the factors assessed in univariate analysis revealed any association with increased toxicity (Table 5) .
Completion of Planned Treatment
Fifty-six (53%) of the patients who received chemotherapy (57% fit and 45% medium fit patients) were able to complete the number of prescribed cycles. Likewise, 25 (48%) required at least 1 level of dose reduction (50% fit and 29% medium fit), and 33 patients (59%) had at least 1 dose delay (64% fit and 43% medium fit). Causes of discontinuation were: Grade 3 to 4 toxicity (65%), cancer recurrence (3%), aggravation of comorbidities (25%), and patient ; P ¼ .009). Median DFS was not reached in the fit or medium fit groups, but this was 26.68 months in unfit patients. The DFS rates (95% CI; number still at risk) according to oncogeriatric group at 3 years after surgery were 79% (70%-88%; n ¼ 51) in fit, 64% (54%-79%; n ¼ 27) in medium-fit, and 46% (31%-61%; n ¼ 17) in unfit patients (log rank, P ¼ .01). Because unfit patients are at high risk of dying from noncancer-related causes, we analyzed DFS related to the use of chemotherapy only in the group of patients considered fit enough to receive chemotherapy (fit and medium fit patients). Neither those who received the treatment nor those who did not reached median DFS, that is, more than half were still disease-free at study end. The DFS rates (95% CI; number still at risk) at 3 years after surgery were 73% (65%-81%; n ¼ 58) in chemotherapy recipients and 58% (47%-69%; n ¼ 37), in nonrecipients (log rank, P ¼ .01).
Sixty-two patients (32%) had died by study end (fit: 17 of 86 [20%]; medium fit: 20 of 55 [36%]; and unfit: 34 of 52 [65%]; P < .001). The fit group had not reached median OS, this was 62.06 months and 34.72 months in medium fit and unfit patients, respectively. Excluding unfit patients (not candidates to receive chemotherapy), the 3-and 5-year OS rates were 88% and 70% in patients who received adjuvant treatment versus 73% and 56% in untreated patients (log rank, P ¼ .10).
Discussion
Our prospective study reports the utility of the CGA as a tool for guiding decisions related to tailored-dose adjuvant therapy in a cohort of 193 patients aged 75 years and older with high-risk stage II and stage III CRC in a clinical setting. The fact that some patients refused treatment and others could not take at least 80% of the total dose planned indicates that there is a gap between medical recommendations and practice in these CRC patients. Because administering adjuvant chemotherapy increases survival as much in the elderly as in younger patients with CRC, 32 chronological age alone
should not be a barrier to accessing the most appropriate treatment. 33 A relevant issue tied to the supposed benefit of chemotherapy is the adherence to the therapy. According to the World Health Organization, adherence is influenced by treatment-related but also by patient-related factors, condition-related factors, and socioeconomic status. 34 Most oncological strategies to reduce toxicity and improve tolerance and adherence are focused on adapting treatment. Nevertheless, CGA identifies patient-and condition-related factors that are not detected in a routine assessment and might influence chemotherapy tolerance, but which might be modifiable through subsequent clinical interventions. 35 For instance, an interesting study by Kalsi et al 36 in
older patients at the start of chemotherapy showed how CGA-based interventions can improve chemotherapy tolerance by modifying coexisting conditions. The decision-making process related to treatment must pay due consideration to patients' values, goals, and preferences after they have received appropriate information about risks and benefits. Although older people might be less willing than younger patients to accept possible side effects, most of them have a desire to be treated. Elkin et al reported a consistent discordance between patients' stated preferences and their physicians' perceptions about desire for information and decision control. 37 In our study up to 14% of patients classified as fit/medium fit refused adjuvant chemotherapy after receiving complete information about the chemotherapy plan and potential toxicity. Factors associated with treatment refusal were polypharmacy and tumor location in the rectum. Other authors have reported a negative correlation between the number of prescriptions and adherence to medication in populations like our elderly people who received oral chemotherapy. 38 Additionally, we have to take into account that polypharmacy can increase the risk of drug interactions with oral chemotherapy, making consultation with a pharmacist a cornerstone of managing elderly patients receiving chemotherapy. This is a factor that should be reviewed with the patients when chemotherapy is going to be prescribed. The other associated factor, rectal cancer, could be explained by the fact that patients might have been more reluctant to undergo additional rounds of chemotherapy because they had already received neoadjuvant chemoradiotherapy and major surgery. Predicting toxicity in elderly patients is an important challenge because the potential effect on functionality and quality of life is much more relevant in this group than in the general population. 43 this question remains unclear because of heterogeneity in different studies' design, populations, and reported outcomes. In contrast to the aforementioned studies, and keeping in mind that every type of malignancy and stage has its own characteristics, it is worth emphasizing that our study was focused on a single disease and used the same treatment scheme for all patients according their geriatric profile. Two recently published risk scales, which include several tumor types and stages, are on the basis of a CGA, and they have shown good predictive value for estimating chemotoxicity in elderly patients. 44 , 45 Hamaker et al suggested that
it is probably more important to determine if a patient is frail than to identify the precise origin of the frailty. 46 In our study, we found no association between toxicity and any other variable, including frailty level, although this can be explained because we had already used CGA to determine which patients would receive dose-adjusted treatment. Likewise, although high VES-13 scores have been shown to predict toxicity in patients aged 75 years or more, 47 our initial selection of patients for chemotherapy already took their frailty profile into consideration, explaining the lack of association between the VES-13 score and toxicity in our patients. The rate of Grade 3 to 4 toxicities of adjuvant chemotherapy in our study is consistent with the range of values reported in other elderly-specific studies, 11, 48 but none of those studies incorporated a geriatric assessment to select patients for the treatment. Chang et al used a tailored-dose escalation of capecitabine considering the RDI, toxic effects, and quality of life during chemotherapy, also reporting a similar rate of toxicity. 49 Regarding oral chemotherapy adherence, most studies in older patients have focused on breast cancer 50 or included multiple types of tumor and chemotherapy schemes. [51] [52] [53] Several studies suggested that completing chemotherapy in the CRC adjuvant setting is associated with longer survival in elderly patients. 54 Decreased completion has been reported with oral chemotherapy and illustrates the difficulty of controlling adherence in the outpatient setting because of the patient's involvement. 55 We were not able to analyze other age-related factors associated with nonadherence to oral chemotherapy, like poor cognitive function or delirium, because we considered these to be a geriatric syndrome, which was an exclusion criterion for receiving adjuvant chemotherapy. Although we started fit patients with standard-dose chemotherapy and medium fit patients with a reduced dose, only 55% of the patients who received chemotherapy could complete !80% of the planned dose. Nevertheless, chemotherapy adherence in this study was consistent with previous studies in heterogenous populations, which reported adherence levels ranging from 49.1% to 70%. 16, 53, 56 Our adherence rates were lower than those presented in the Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trials, in which 74% of the patients completed their treatment, probably because that data came from a subgroup of selected elderly patients aged 70 to 75 years. 15 The proportion of patients who completed the 8 cycles prescribed in the study by Chang et al was also higher (87%), but only 50% of them received !80% of the planned dose. 49 On the contrary, Van Erning et al reported the same adherence rate as ours (55%) in their study in patients aged 70 years or older in a clinical practice setting. 48 Although fit patients experienced slightly (P > .05) more toxicity along with more delay and dose reduction than medium fit patients, they were more likely to complete !80% of the planned dose. This is probably related to their higher initial chemotherapy dose (more risk of toxicity) but also their better overall health profile (more capacity to overcome toxicity). Interestingly, we found that noncompletion of the therapy as prescribed appeared to be related to treatment-related factors such as toxicity (as in younger populations), but the multivariate analysis also showed the importance of social support. Previous reports have highlighted the importance of this issue for treatment completion in the elderly population, 53 and this is also an area amenable to modification through geriatric intervention. Consequently, improving adherence requires the involvement of a multidisciplinary team that plans strategies for reducing chemotherapy side effects and provides patients and caregivers with information on toxicity and how to manage it. The multidisciplinary team should also include a social worker that finds social care facilities when there is a lack of social support.
In our study, we found a significant DFS and OS benefit in patients who received chemotherapy. Some of this is because of the expected beneficial effect of chemotherapy, but it might also have to do in part with fit and medium fit patients being less likely than unfit patients to suffer from competing causes of mortality. To make effective decisions on which older patients would benefit from adjuvant therapy, it is necessary to weigh the risk of recurrence or death against the risk for toxicity and the patient's life expectancy irrespective of cancer. As previously published by our group, CGA has predictive value in establishing the risk of dying from cancer versus other causes. 57 As for the association between adherence and survival in the present study, the small sample size precluded analysis. Major strengths in this study are its prospective design, its standardized CGA, and the fact that the sample was drawn from all recently diagnosed patients with CRC who were candidates for adjuvant therapy, before the initiation of chemotherapy and without any previous selection. Moreover, unlike other studies that included several tumor types, we focused on a specific group of patients with a single disease.
However, several limitations should also be noted. Our study took place in a single institution, and although the components of the CGA have been validated in a geriatric population, the CGA model we used was designed at our center and might differ from those used elsewhere. Likewise, the frailty assessment did not include any physical performance measures, which have been shown to enhance the predictive ability of these assessments, 58 and we did not collect information about socioeconomic status.
Conclusion
In summary, we found CGA to be a highly effective multidimensional approach for reclassifying the initial therapeutic decision (only on the basis of histology and tumor stage), taking into account patient parameters related to aging. The present study provides an important contribution on the treatment decision-making process, describes CGA-based strategies for helping clinicians to identify elderly patients who might benefit from safe and suitable adjuvant chemotherapy versus those who will not. Specific trials in elderly patients are needed to determine the utility of CGA for predicting completion and benefit of chemotherapy as well as the most suitable schemes for these patients. Last, treatment refusal by a significant proportion of patients should be a cause of concern and highlights the need for a personalized approach to therapy that takes into account patients' values and preferences.
Clinical Practice Points
Because aging is a heterogeneous process, the selection of elderly CRC patients for adjuvant therapy remains a challenge. Comprehensive geriatric assessment has shown utility in defining multiple frailty levels and guiding treatment strategy, not only on the basis of chronological age but also on the type of aging profile. A relevant issue linked to the supposed benefit of chemotherapy in older populations is the rate of adherence to the treatment. In this prospective study we assessed adherence to a tailored-dose adjuvant therapy on the basis of the CGA, in a cohort of older (75 years and older) CRC patients by identifying factors associated with patient's refusal, toxicity, and treatment completion. According to CGA, patients were classified into 3 groups: fit, medium fit, and unfit, to receive standard therapy, adjusted treatment and best supportive care, respectively. Among the group of fit and medium fit considered for receiving chemotherapy, 14% denied treatment, 23% experienced any Grade 3 to 4 toxicity and, finally, 55% completed !80% of the dose prescribed initially. Polypharmacy and rectal location were factors that influenced patient's refusal whereas not presenting toxicity and having social support were associated with better completion. None of the potential predictor factors of toxicity resulted as significant, probably because of previous dose adaptation. The present study provides an important contribution on the treatment decision-making process, giving strategies, on the basis of CGA, to help clinicians classify elderly patients who might benefit from safety suitable adjuvant chemotherapy and detecting factors that influence adherence that can be reversible with CGAbased interventions.
